BioStock: Saniona carves path to disrupt the epilepsy market

Saniona’s expertise in ion channel modulation has resulted in a vast pipeline of drug candidates targeting a number of central nervous system disorders. However, the company’s main focus is epilepsy, where the medical need and market potential are quite significant. The lead candidate in the epilepsy programme, SAN711, is poised for proof-of-concept studies. To secure its development, and to bring forward other epilepsy candidates towards the clinic, Saniona is carrying out a SEK 140 million rights issue.

Read the article at biostock.se:

Saniona carves path to disrupt the epilepsy market - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/